ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO584

Assessing Clinical Outcomes of ANCA Vasculitis in the Post PEXIVAS Era: A Single Centre Retrospective Analysis

Session Information

Category: Glomerular Diseases

  • 1302 Glomerular Diseases: Immunology and Inflammation


  • Rajakariar, Ravindra, Barts Health NHS Trust, London, London, United Kingdom
  • Hall, Charles, Barts Health NHS Trust, London, London, United Kingdom
  • Carruthers, Jack E., Barts Health NHS Trust, London, London, United Kingdom
  • Wells, James, Barts Health NHS Trust, London, London, United Kingdom

The PEXIVAS trial (2018) showed no outcome benefit with the routine use of plasma-exchange (PLEX) in patients with ANCA vasculitis and eGFR < 50mL/min. As a result, our clinical practice changed in favour of no PLEX and replacing a standard steroid wean with a fast steroid taper, thus altering the burden of immunosuppression in patients with ANCA vasculitis. We performed a retrospective analysis of a cohort of patients with ANCA vasculitis and renal involvement to determine whether this change in management impacted on patient outcomes and infections requiring hospitalisation.


We audited a cohort of ANCA vasculitis patients with renal involvement under follow-up at a tertiary centre diagnosed in the last 20 years. We collected demographic and clinical data including induction agent, PLEX regimen, and details of infections due to immunosuppression. The outcomes measured were patients who were in remission at one year and infections that required hospitalisation or CMV viraemia within 1 year of diagnosis


A total of 134 patients were identified, 91 diagnosed pre-PEXIVAS and 43 post-PEXIVAS. 6 patients died from COVID-19 by 1 year in the post-PEXIVAS group, these patients were excluded from analysis. Pre- and post-PEXIVAS mean age (60.6 yrs and 59 yrs respectively) and sex ratio (54/91 (59%) and 24/43 (55%)) were similar. The preferred induction agent pre-PEXIVAS was cyclophosphamide (65/91 (75%)) whilst there was a move to Rituximab in the post-PEXIVAS cohort(13/43 (48%)). Pre-PEXIVAS, 27/91 (29%) patients underwent PLEX versus 2/43 (4%) post-PEXIVAS.
Remission rates at 1 year after diagnosis were similar between the two cohorts (pre: 65/91 (71.4%); post: 23/37 (53%); p=0.18 by Fisher’s exact test). Infections that required hospitalisation were not significantly different but there was a trend to lower rate of admissions (pre: 16/91 (17.6%); post: 5/37 (12.2%); p=0.61 by Fisher’s exact test).


Our results suggest that change in clinical management after PEXIVAS was not associated with poorer outcomes in relation to treatment response and there was no significant difference in infections requiring hospitalisation at 1 year in patients with ANCA vasculitis. Our work complements recent findings that PLEX was not associated with improved rates of renal replacement therapy or mortality (Nezam et al. 2022).